A trial looking at chemotherapy and rituximab for non Hodgkin lymphoma (CORAL)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Blood cancers
High grade lymphoma
Lymphoma
Non-Hodgkin lymphoma

Status:

Results

Phase:

Phase 3

This trial looked at chemotherapy and rituximab for people with a type of non Hodgkin lymphoma called diffuse large B cell lymphoma. It recruited people whose lymphoma had come back or stopped responding to treatment. This trial was supported by Cancer Research UK.

Doctors usually treat this group of people with chemotherapy followed by high dose chemotherapy and a stem cell transplant.

This trial looked at 2 standard chemotherapy combinations called DHAP and ICE used to treat people with diffuse large B cell lymphoma before having a stem cell transplant. DHAP includes the chemotherapy drugs cisplatin and cytarabine, with the steroid dexamethasone. ICE is ifosfamide, carboplatin and etoposide.

Earlier research showed that a type of biological therapy called rituximab might help DHAP and ICE chemotherapy to work better. So both groups in this trial also had rituximab.

The trial also looked at rituximab after a stem cell transplant to see if it could further reduce the risk of the lymphoma coming back.

The aims of the trial were to find out

  • If DHAP and rituximab is better than ICE and rituximab for people with diffuse large B cell lymphoma
  • How useful rituximab is for this group of patients after a stem cell transplant

Summary of results

The trial team found no difference between the people who had DHAP and rituximab (DHAP-R) and the people who had ICE and rituximab (R-ICE).

392 people with diffuse large B cell lymphoma had the treatment in this trial. The trial was divided in into 2 parts. In the first part of the trial

  • Half had DHAP-R
  • Half had R-ICE

The treatment worked for 206 people. They then joined the second part of the trial. And went on to have high dose chemotherapy followed a stem cell transplant. After the transplant

  • Half had rituximab for 1 year– doctors call this ‘maintenance treatment’
  • Half had no further treatment but had regular checkups with their doctor

The trial team analysed the results of the first part of the trial after monitoring the people in the trial for about 3 years. They compared the people who had DHAP-R with the people who had R-ICE to see how well the 2 different treatments worked. They found no difference between the 2 different groups.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor D. Linch

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
GELA
National Institute for Health Research Cancer Research Network (NCRN)

Other information

This is Cancer Research UK trial number CRUK/06/006

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 338

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think